Date: 2015-06-23
Type of information: Establishment of a new subsidiary in the US
Compound:
Company: Affimed (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: establishment of a new subsidiary in the US
Action mechanism: bispecific antibody. Affimed is developing next-generation bispecific antibodies.Theses antibodies are called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights, AFM13, AFM11 and AFM21. AFM13 is initially being developed for the salvage treatment of Hodgkin Lymphoma patients. AFM11 will initially be developed for relapsed/refractory aggressive Non- Hodgkin Lymphoma and AFM21 targets the treatment of various solid tumors.
Disease:
Details: * On June 23, 2015, Affimed, a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced that it has established operations in the United States. The Company also announced that Caroline Stewart and Dr. Oscar Kashala have joined the Company as Head of Investor Relations & Communication and Vice President, Medical US, respectively. Caroline brings nearly twenty years of combined experience on Wall Street and in the pharmaceutical industry to the Company. Caroline joins Affimed from H.C. Wainwright, where she served as Managing Director and Senior Biotechnology Analyst. During her tenure as Senior Biotechnology Analyst and V.P. at Piper Jaffray she was named Wall Street Journal\'s \"Best on the Street\" (#4) and Financial Times / Starmine #3 Best Stock Picker 2008. More recently, she served as Director of Investor Relations at Merck KGaA and also as a Senior Manager of US Finance for Sanofi\'s oncology drugs. Her experience is enhanced by her Bachelor\'s degree in Chemistry from Barnard College of Columbia University and Master\'s degrees in Chemistry and Biology from Brandeis University. Oscar is a biopharmaceutical executive with expertise in early to late-stage development of oncology and infectious diseases products. He held positions of increasing responsibility at Cambridge Biotech/Aquila Biopharmaceuticals, Lexigen Pharmaceuticals, Millennium Pharmaceuticals, and EMD Serono, where he led the efforts to develop immunotherapy for solid tumors and hematologic cancers. At Millennium, he contributed to the development of bortezomib (Velcade®) in multiple myeloma, and led its development in solid tumors. Oscar managed a portfolio of more than 20 different vaccines and antibody therapies for cancer, and forged collaborations and alliances with the US Government and academic institutions across the US and Europe. He held faculty positions at universities in the US and abroad, and authored over 80 peer-reviewed articles, abstracts and book chapters. He joins talented peers to support the medical team in translating the Company\'s research and development efforts into novel therapeutic options for cancer patients. Dr. Kashala is the recipient of several prestigious awards from WHO and NIH/NCI. He holds a Doctor of Medicine, Surgery and Obstetrics degree (M.D.) from the University of Kinshasa Medical School, a Specialist of Pathology and Oncology degree from a combined program of the University of Kinshasa and the University of Geneva medical schools, and a Doctor of Science degree in cancer biology from Harvard University.
Financial terms:
Latest news:
